Clinical Trials

Inclusion Criteria:

• Age ≥ 18 years.
• Undifferentiated inflammatory arthritis suspected to be early rheumatoid arthritis (RA) by the evaluating clinician with clinical synovitis of ≥ 1 joint and ≥ 1 other tender joint but not fulfilling classification criteria.
• Symptom duration ≤ 2 years.
• Arthralgias suspected to be early RA by the evaluating clinician without clinical evidence of synovitis.

Exclusion Criteria:

• Unwillingness or inability to return to Mayo Clinic for research follow-up visits.
• Current or previous (within the previous 6 months) use ofDMARDs – prednisone (≥ 10 mg/day), methotrexate,hydroxychloroquine, sulfasalazine, leflunomide, adalimumab, certolizumab, etanercept, golimumab, infliximab, abatacept, tocilizumab, sarilumab, tofacitinib, rituximab, or anakinra.
• Contraindications to contrast-enhanced MRI ( renal insufficiency with estimated GFR ≤ 60 ml/min/1.73 m², extreme claustrophobia, metal implants or devices that contraindicate MRI).
• Contraindications to contrast-enhanced PCD-CT (eGFR < 30, history of previous contrast allergic reaction, history of premedication prior to iodinated contrast).
• Personal history of another definite autoimmune or inflammatory rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus, polymyositis, dermatomyositis, vasculitis, gout, or CPPD) diagnosed by a rheumatologist, excluding secondary Sjogren’s syndrome.
• Women who are pregnant or nursing.
• Personal history of psoriasis diagnosed by a primary care physician or dermatologist.
• Personal history of inflammatory bowel disease diagnosed by a gastroenterologist.
• Unsuitability to participate in the judgment of a study investigator.